SLC5A2 and chronic kidney disease: Recent treatment guidelines for CKD and its risk factors include sodium-glucose cotransporter-2 (SGLT-2) inhibitors [6, 7], which have demonstrated beneficial clinical efficacy on kidney disease progression and mortality, irrespective of diabetes status [1, 8].